Evaluating Vitamin D Content in Mushrooms

NCT ID: NCT01815437

Last Updated: 2017-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate how much vitamin D is present in a mushroom supplement. This supplement contains an extract from mushrooms that have been exposed to sunlight. The mushroom supplement will be compared to non-commercially available vitamin D supplements produced in a Goo Manufacturing Practices (GMP)-licensed facility.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mushrooms have the capability to produce vitamin D in a similar way to human skin. When exposed to ultraviolet light, mushrooms will convert a precursor to vitamin D. This reaction produces large amounts of vitamin D. This study is comparing a natural source of vitamin D to a synthetic source of vitamin D and will help determine if mushrooms are a novel source for this essential nutrient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2000 IU Vitamin D3- Cholecalciferol

Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.

Group Type ACTIVE_COMPARATOR

Cholecalciferol

Intervention Type DIETARY_SUPPLEMENT

2000 IU crystalline cholecalciferol once/day for 12 weeks

2000 IU Vitamin D2- Ergocalciferol

Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.

Group Type ACTIVE_COMPARATOR

Vitamin D2 - Ergocalciferol

Intervention Type DIETARY_SUPPLEMENT

2000 IU vitamin D2, ergocalciferol once/day for 12 weeks

2000 IU Mushroom Vitamin D2

Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks

Group Type EXPERIMENTAL

Mushroom Vitamin D2

Intervention Type DIETARY_SUPPLEMENT

2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks

Mushroom Extract

Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.

Group Type PLACEBO_COMPARATOR

Mushroom Extract

Intervention Type DIETARY_SUPPLEMENT

Same quantity of mushroom extract in a capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mushroom Vitamin D2

2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks

Intervention Type DIETARY_SUPPLEMENT

Cholecalciferol

2000 IU crystalline cholecalciferol once/day for 12 weeks

Intervention Type DIETARY_SUPPLEMENT

Vitamin D2 - Ergocalciferol

2000 IU vitamin D2, ergocalciferol once/day for 12 weeks

Intervention Type DIETARY_SUPPLEMENT

Mushroom Extract

Same quantity of mushroom extract in a capsule

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ergocalciferol Ercocalciferol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All healthy adults, male and female, age 18-64 years

Exclusion Criteria

* Currently taking, or having taken less than one month prior to start of study, a prescription of 50,000 IU of vitamin D2 or 2000 IU vitamin D2 or vitamin D3
* Allergy to mushrooms
* History of elevated calcium (\>10.4 mg%)
* Patients with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
* Supplementation with over the counter formulations of vitamin D2 or vitamin D3
* Subjects with a history of an adverse reaction to orally administered vitamin D.
* Subjects who are taking oral Dilantin or glucocorticoids.
* Exposure to a tanning bed or tanning on a beach for more than eight hours with no sunscreen within 2 weeks prior to start of study.
* History of intestinal malabsorption (i.e. cystic fibrosis, fat malabsorption syndrome, Crohn's Disease, gastric bypass surgery).
* Subjects with any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael F Holick, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Boston Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boston Medical Center

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. doi: 10.1056/NEJMra070553. No abstract available.

Reference Type BACKGROUND
PMID: 17634462 (View on PubMed)

Rovner AJ, O'Brien KO. Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med. 2008 Jun;162(6):513-9. doi: 10.1001/archpedi.162.6.513.

Reference Type BACKGROUND
PMID: 18524740 (View on PubMed)

Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics. 2009 Sep;124(3):e362-70. doi: 10.1542/peds.2009-0051. Epub 2009 Aug 3.

Reference Type BACKGROUND
PMID: 19661054 (View on PubMed)

Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008 Dec;88(6):1519-27. doi: 10.3945/ajcn.2008.26182.

Reference Type BACKGROUND
PMID: 19064511 (View on PubMed)

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006 Mar 24;311(5768):1770-3. doi: 10.1126/science.1123933. Epub 2006 Feb 23.

Reference Type BACKGROUND
PMID: 16497887 (View on PubMed)

Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009 Feb 23;169(4):384-90. doi: 10.1001/archinternmed.2008.560.

Reference Type BACKGROUND
PMID: 19237723 (View on PubMed)

Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008 Mar;93(3):677-81. doi: 10.1210/jc.2007-2308. Epub 2007 Dec 18.

Reference Type BACKGROUND
PMID: 18089691 (View on PubMed)

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. doi: 10.1210/jc.2010-2704. Epub 2010 Nov 29.

Reference Type BACKGROUND
PMID: 21118827 (View on PubMed)

Pietras SM, Obayan BK, Cai MH, Holick MF. Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years. Arch Intern Med. 2009 Oct 26;169(19):1806-8. doi: 10.1001/archinternmed.2009.361. No abstract available.

Reference Type BACKGROUND
PMID: 19858440 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MU100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

25-Hydroxyvitamin D Pharmacokinetic Study
NCT03401541 COMPLETED EARLY_PHASE1